High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Clonal cytopenias, particularly those with TET2 mutations, represent a significant challenge in hematologic oncology.
• Investigating novel therapeutic strategies for these conditions is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of high-dose intravenous (IV) ascorbic acid in patients with TET2-mutated clonal cytopenias.
• To assess the safety and tolerability of this treatment regimen.

Main Methods:

• A phase 2 clinical trial was conducted.
• Ten patients with TET2 mutant clonal cytopenia were enrolled.
• High-dose IV ascorbic acid was administered.
• Response assessment was performed using International Working Group Myelodysplasia Syndromes/Neoplasms criteria at week 20.

Main Results:

• Eight out of 10 patients were eligible for response assessment.
• No responses were observed in any eligible patients at week 20.
• The study did not report specific adverse events but focused on response rates.

Conclusions:

• High-dose IV ascorbic acid demonstrated no efficacy in treating TET2 mutant clonal cytopenia in this phase 2 trial.
• Further research may be needed to explore alternative therapies for this patient population.